PHILADELPHIA, Oct. 2, 2017 /PRNewswire/ -- Halo Labs announces the European launch of their new low volume, high throughput biopharmaceutical particle analysis system called the HORIZON at MIBio 2017 in Cambridge, U.K on October 4th. The new system analyzes subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity while using far less sample volume through the use of the novel technique Backgrounded Membrane Imaging.
"We are excited to launch HORIZON in Europe," says Dr. Robert Hart, CEO of Halo Labs. "Europe has some of the most innovative biopharma companies in the world. HORIZON is well positioned to dramatically advance how particle analysis is conducted in protein drugs, helping pharma researchers get a quick and accurate grasp on the stability and sterility of their products. The speed and flexibility of the HORIZON will help our customers reduce development time and patient risk of immunogenicity."
With the increase in US adoption of the HORIZON technology, Halo Labs is now extending their focus on European expansion. Halo Labs will be presenting a talk and hosting a booth at MIBio in Cambridge, U.K, and presenting a poster at PEGS Europe in Lisbon, Portugal in mid November. Halo Labs will also showcase HORIZON in the United States; presenting a booth at Well Characterized Biologicals in Rockville, MD, followed by a poster at AAPS San Diego, CA mid November. For more information about purchasing the HORIZON, email email@example.com or visit the Halo Labs website https://halolabs.com/.
About Halo Labs: Halo Labs is a scientific equipment manufacturer commercializing biopharmaceutical analysis instrumentation. The company was named Philadelphia Life Science Startup of 2012. Halo Labs is venture backed by BioAdvance and the HORIZON system is funded by prestigious research grants from NIST and the FDA.
SOURCE Halo Labs